CM
SWTX

Castleark Management’s SpringWorks Therapeutics SWTX Stock Holding History

Castleark Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-105,160
Closed -$3.96M – 305
2024
Q2 		$3.96M Buy
105,160
+26,810
+34% +$1.13M 0.16% 138
2024
Q1 		$3.86M Buy
78,350
+5,300
+7% +$245K 0.16% 142
2023
Q4 		$2.67M Buy
+73,050
New +$1.91M 0.12% 168
2021
Q4 		– Sell
-89,086
Closed -$5.65M – 362
2021
Q3 		$5.65M Sell
89,086
-2,600
-3% -$200K 0.22% 114
2021
Q2 		$7.56M Sell
91,686
-2,270
-2% -$172K 0.25% 108
2021
Q1 		$6.91M Buy
93,956
+18,300
+24% +$1.43M 0.25% 114
2020
Q4 		$5.49M Buy
+75,656
New +$4.87M 0.21% 133

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Castleark Management's SWTX Position: Q3 2024 in Review

Castleark Management sold out of SpringWorks Therapeutics (SWTX) in Q3 2024, closing a stake of 105,160 shares — an estimated $3.96M sold.

Castleark Management first reported a position in SWTX in Q4 2020 and held it in 7 quarters. The position peaked at $7.56M in Q2 2021. 226 funds tracked by Wall St. Rank hold SWTX as of Q3 2024.

  • Castleark Management reported no remaining SpringWorks Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Castleark Management sold 105,160 SpringWorks Therapeutics shares in Q3 2024, an estimated $3.96M.
  • Castleark Management first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 7 quarters.
  • Castleark Management's SpringWorks Therapeutics position peaked at $7.56M in Q2 2021.
  • 226 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2024.

Based on Castleark Management's 13F filing for Q3 2024, filed 15 Nov 2024.